(6Z)-1,2,3,4,5,8-hexahydro-1,3-diazocine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: (6Z)-1,2,3,4,5,8-hexahydro-1,3-diazocine
• 化学式: C₆H₁₂N₂
• 分子量: 112.17
• InChiKey: IMNVLGWLLKRNRE-UPHRSURJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  8
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  24.1
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• [EN] BETA-LACTAMASE INHIBITORS<br/>[FR] INHIBITEURS DE BÊTA-LACTAMASE
  申请人：VENATORX PHARMACEUTICALS INC

  公开号：WO2014151958A1

  公开（公告）日：2014-09-25

  Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

  本文描述了一些能够调节β-内酰胺酶活性的化合物和组合物。在某些实施例中，所述化合物能够抑制β-内酰胺酶。在特定实施例中，所述化合物在治疗细菌感染方面具有用处。
• [EN] SPIROQUINOXALINE DERIVATIVES AS INHIBITORS OF NON-APOPTOTIC REGULATED CELL-DEATH<br/>[FR] DÉRIVÉS DE SPIROQUINOXALINE EN TANT QU'INHIBITEURS DE LA MORT CELLULAIRE RÉGULÉE NON APOPTOTIQUE
  申请人：HELMHOLTZ ZENTRUM MÜNCHEN DEUTSCHES FORSCHUNGSZENTRUM FÜR GESUNDHEIT UND UMWELT GMBH

  公开号：WO2015007730A1

  公开（公告）日：2015-01-22

  The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterised by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role. The compounds and pharmaceutical compositions described herein are also useful in the treatment of a condition, disorder or disease that is characterised by oxidative stress or where oxidative stress is likely to play or plays a substantial role; and/or a condition, disorder or disease that is characterised by activation of (1) one or more components of the necrosome; (2) death domain receptors; and/or (3) Toll-like receptors; and/or (4) players in ferroptotic/ferroptosis signalling, or where activation of any one of (1) to (3) and/or (4) is likely to play or plays a substantial role.

  本发明涉及抑制非凋亡调节细胞死亡的化合物，以及包含这些化合物的制药组合物。此外，本发明还涉及这些化合物和制药组合物在治疗中的应用，特别是在治疗由非凋亡调节细胞死亡特征化的疾病、疾病或疾病中，或者在非凋亡调节细胞死亡可能发挥或发挥重要作用的情况下。本文描述的化合物和制药组合物还可用于治疗由氧化应激特征化的疾病、疾病或疾病，或者氧化应激可能发挥或发挥重要作用的情况；和/或由（1）一个或多个死亡体受体的成分；（2）死亡结构域受体；和/或（3）Toll样受体的激活；和/或（4）铁死亡/铁死亡信号通路中的参与者的特征化，或者激活（1）至（3）和/或（4）中的任何一个可能发挥或发挥重要作用的情况。
• BETA-LACTAMASE INHIBITORS
  申请人：VENATORX PHARMACEUTICALS, INC.

  公开号：US20160024121A1

  公开（公告）日：2016-01-28

  Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.

  本文介绍了一些调节β-内酰胺酶活性的化合物和组合物。在某些实施例中，所述化合物抑制β-内酰胺酶。在某些实施例中，所述化合物可用于治疗细菌感染。
• ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS
  申请人：VenatoRX Pharmaceuticals, Inc.

  公开号：US20150361108A1

  公开（公告）日：2015-12-17

  Described herein are compounds and compositions that modulate the activity of beta-lactamases and methods thereof. In some embodiments, the compounds described herein are biologically hydrolyzed to a beta-lactamase inhibitor. In certain embodiments, the compounds described herein are useful for the treatment of bacterial infections.

  本文描述了调节β-内酰胺酶活性的化合物和组合物及其方法。在某些实施例中，本文所描述的化合物在生物体内水解成β-内酰胺酶抑制剂。在某些实施例中，本文所描述的化合物可用于治疗细菌感染。
• Spiroquinoxaline derivatives as inhibitors of non-apoptotic regulated cell-death
  申请人：Helmholtz Zentrum Munchen—Deutches Forschungszentrum Fur Gesundheit und Umwelt

  公开号：US10280179B2

  公开（公告）日：2019-05-07

  The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds and pharmaceutical compositions in therapy, in particular in the treatment of a condition, disorder or disease that is characterized by non-apoptotic regulated cell-death or where non-apoptotic regulated cell-death is likely to play or plays a substantial role. The compounds and pharmaceutical compositions described herein are also useful in the treatment of a condition, disorder or disease that is characterized by oxidative stress or where oxidative stress is likely to play or plays a substantial role; and/or a condition, disorder or disease that is characterized by activation of (1) one or more components of the necrosome; (2) death domain receptors; and/or (3) Toll-like receptors; and/or (4) players in ferroptotic/ferroptosis signalling, or where activation of any one of (1) to (3) and/or (4) is likely to play or plays a substantial role.

  本发明涉及作为非凋亡调节细胞死亡抑制剂的化合物，以及含有此类化合物的药物组合物。此外，本发明还涉及此类化合物和药物组合物在治疗中的用途，特别是在治疗以非凋亡调节性细胞死亡为特征或非凋亡调节性细胞死亡可能起或起重要作用的病症、紊乱或疾病中的用途。本文所述的化合物和药物组合物还可用于治疗以氧化应激为特征的病症、紊乱或疾病，或氧化应激可能起作用或起重要作用的病症、紊乱或疾病；和/或以（1）坏死体的一种或多种成分；（2）死亡结构域受体；和/或（3）Toll 样受体；和/或（4）铁凋亡/铁变态反应信号的激活为特征的病症、紊乱或疾病，或（1）至（3）和/或（4）中的任何一种激活可能起或起重要作用的病症、紊乱或疾病。